Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2007-08-28
2007-08-28
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S620000, C423S087000, C423S088000, C423S601000, C423S602000
Reexamination Certificate
active
10438856
ABSTRACT:
A process for preparing As4O6comprises successively heating and cooling a mixture of natural Sinsuk and 40% alcohol in a ratio of about 1: about 1 for about 1 to about 2 hour(s) resulting in a product, successively washing the product with distilled water thereby forming washed precipitates, maintaining the washed precipitates at about −40° C. for 24 hours, defrosting, filtering, and drying the precipitates, and successively heating and cooling the precipitates to obtain the final As4O6product.
REFERENCES:
KOREAPAT abstract 2000:013552 (2000).
Guo-Qiang Cehn et al., “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL) : I. As2O3Exerts Dose-Dependent Dual Effects on APL Cells”, Blood, vol. 89, No. 9, May 1, 1997: pp. 3345-3353.
Stefan Müller et al., “Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus”, The EMBO Journal vol. 17 No. 1 pp. 61-70, 1998.
Zhou, D-C et al., “Arsenic trioxide is an equipotent inducer of apoptosis in adrogen-dependent and androgen-independent LNCaP prostate cancer cell sublines”, Albert Einstein Cancer Center, Bronx, NY 10467 and Mount Sinai Medical Center, New York, NY 10029, #3999; Proc. American Association Cancer Res. 39, Mar. 1998.
Yang, C.H. et al; “Cytotoxcity of arsenic trioxide in cancer cell lines”, Department of Oncology, National Taowan University Hospital & Chung-Shan South Road, Taipei, Taiwan 10016; #1552; Proc. Amer. Assoc. Cancer Res. 39, Mar. 1998.
Dai, J. et al.; “Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells”, Mount Sinai School of Medicine, New York, NY 10029; #468; Proc. Amer. Assoc. Cancer Res. 39, Mar. 1998.
Xiao-Jun Huang et al.; “Arsenic trioxide induces apoptosis of myeloid leukemia cells by activiation of caspases via an alternative transduction pathway”; Department of Oncology, Montefiore Medical Center, Bronx, NY 10467; #614; Pro. Amer. Assoc. Cancer Res. 39, Mar. 1998.
Koshizuka, K. et al.; “Combined effect of organic arsenical, melarsoprol and all-trans-retinoic acid on the inhibition of human brest and prostate cancers in vitro in vivo”, #725 Division of Hematology/Oncology, Division of Pathology. Depts. Of Medicine, UCLA School of Medicine, Cedar-Sinai Medical Center, Los Angeles, CA, Second Dept. Of Surgery, Yamanashi Medical University, Yamanashi, Japan; #725; Proc. Amer. Assoc. Cancer Res. 39, Mar. 1998.
Gillies, F. et al.; “Identification of an APL specific golgin-like gene down regulated by ATRA and Arsenic”; Molecular Biology and Cellular Biology Programs, Sloan-Kettering Institute, MSKCC, New York, NY 10021; #3048; Proc. Amer. Assoc. Cancer Res. 39, Mar. 1998.
Steven Soignet et al.; “Clinical and laboratory studies in leukemia of an organic arsenical, melarsoprol”, Memorial Sloan-Kettering Cancer Center, New York, NY; #10; American Society of Clinical Oncology, Website, No date.
Arsenic and retinoid acid: towards anti-leukemia treatments targeted on the incogene?; website, No Date.
Dr. Raymond P. Warrell et al.; “Promising New Treatment for Acute Promyelocytic Leukemia using Arsenic-Based Compound”; News from MSKCC: Press Releases, New Orleans, Mar. 30, 1998; Memorial Sloan-Kettering Cancer Center.
Kehri et al., Natl. Acad. Sci. Lett. (India), 9(10), 301-2, Abstract only, 1986.
Dictionary page fromDonguibogam(Jan. 10, 1991) pp. 1222, describing “BEESANG” with sworn translation of dictionary page by translator, Ae-Young Song.
Bae Ill-Ju
Doo Myoung-Sool
Eun Choong-Ki
Kang Tae-Bong
Kim Jong-Bae
Bae Ill-Ju
Hopkins Susanne M.
Nath Gary M.
Pak John
The Nath Law Group
LandOfFree
Anti-cancer therapy agent of arsenic hexoxide (As 4 O 6 ) of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer therapy agent of arsenic hexoxide (As 4 O 6 ) of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer therapy agent of arsenic hexoxide (As 4 O 6 ) of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3872350